Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)

被引：0
|
作者：
Kovacs, Steven J.
Ke, June
Praestgaard, Jens
Barve, Avantika
Zhang, Jie
Maietta, Robert
Sunkara, Gangadhar
Stein, Daniel S.
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S977 / S977
页数：1
相关论文
共 50 条
  • [21] Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol
    Steven L. Bramer
    William P. Forbes
    Clinical Pharmacokinetics, 1999, 37 : 25 - 32
  • [22] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Tortorici, Michael A.
    Toh, Melvin
    Rahavendran, S. V.
    LaBadie, Robert R.
    Alvey, Christine W.
    Marbury, Thomas
    Fuentes, Ernesto
    Green, Matthew
    Ni, Grace
    Hee, Brian
    Pithavala, Yazdi K.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1370 - 1380
  • [23] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [24] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [25] Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
    Wang, Jing
    Wang, Xiaodong
    Zhang, Zhi-Yi
    Arora, Sujata
    Lu, Sharon
    Kansra, Vikram
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 686 - 693
  • [26] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Michael A. Tortorici
    Melvin Toh
    S. V. Rahavendran
    Robert R. LaBadie
    Christine W. Alvey
    Thomas Marbury
    Ernesto Fuentes
    Matthew Green
    Grace Ni
    Brian Hee
    Yazdi K. Pithavala
    Investigational New Drugs, 2011, 29 : 1370 - 1380
  • [27] Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
    Abel, Samantha
    Davis, John D.
    Ridgway, Caroline E.
    Hamlin, Julia C.
    Vourvahis, Manoli
    ANTIVIRAL THERAPY, 2009, 14 (06) : 831 - 837
  • [28] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [29] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [30] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    Drugs in R&D, 2021, 21 : 375 - 384
12345